---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-105485"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:44:55.976249+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences Q2 net loss $2.4M; cash $5.2M; Gemini data due Q3

## Summary
- Net loss for Q2 2025 was $2.4M ($7.01 per share), improved from $8.4M ($246.27) in Q2 2024.
- Cash and equivalents $5.2M at June 30, 2025, down from $6.5M at Dec 31, 2024; funds operations through Dec 2025.
- Completed dosing in Phase 1b Gemini study in CKD; topline data expected later Q3 2025.
- Raised $4M gross proceeds from public offering in May 2025.
- Cash used in operations was $4.7M in Q2 2025 vs. $5.3M in Q2 2024.

## SEC filing metadata
- accession: 0000950170-25-105485
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017025105485/0000950170-25-105485-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017025105485/revb-20250808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-105485
- JSON: https://secwatch.observer/filing/0000950170-25-105485.json
- Plain text: https://secwatch.observer/filing/0000950170-25-105485.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.